Clinical trials
HER2 + Gastric Cancer clinical trials
Below are recruiting her2 + gastric cancer clinical trials, each written for real people, not researchers. We’re tracking 145 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06123494RecruitingPhase 3
A trial of SHR-A1811 for HER2-positive gastric cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07855640Recruiting
Immunotherapy plus chemo for advanced stomach cancer with fluid in belly
This trial tests a new combination for advanced stomach cancer that has spread and caused fluid buildup in the belly (malignant ascites). It combines an immunotherapy drug (anti-PD-1) with standard chemotherapy and a targeted chemotherapy given directly into the belly to see if it can shrink the cancer and help you feel better.
Hangzhou, ZhejiangAges 18–75 - NCT05975749RecruitingPhase 2
Trastuzumab, serplulimab, and chemo after stomach cancer surgery
This Phase 2 study looks at whether adding serplulimab to trastuzumab and chemotherapy after surgery can lower the chance of stomach cancer coming back. It is for people with HER2-positive stage II–III stomach adenocarcinoma who have already had curative surgery with lymph node removal.
Shanghai, Shanghai MunicipalityAges 20–80 - NCT04660760RecruitingPhase 2
Comparing two treatments for advanced stomach cancer after first treatment
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
Birmingham, AlabamaAges 18 years+ - NCT06221748RecruitingPhase 2/Phase 3
Study of DV with cadonilimab for HER2-positive stomach cancer
This trial tests a combination of two drugs (DV and cadonilimab) for people with HER2-positive stomach or gastroesophageal junction cancer that has grown after first treatment. It aims to see if this combo can help when standard options have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07818018RecruitingPhase 1/Phase 2
Study of 2141-V11 for esophageal, stomach, or junction cancer
This trial tests a new drug called 2141-V11 in people with advanced esophageal, stomach, or gastroesophageal junction cancer. It aims to see if adding this drug to your current treatment can help control the cancer better.
Basking Ridge, New JerseyAges 18 years+ - NCT06487429RecruitingPhase 2
Short radiation followed by combo therapy for HER2+ stomach cancer
This trial tests a new approach for stomach cancer that has spread to nearby tissues but not to other organs. You would get a short course of radiation, followed by a combination of targeted therapy (Disitamab Vedotin), chemotherapy (S-1), and immunotherapy (Sintilimab) before surgery to shrink the tumor and improve outcomes.
Wuhan, HubeiAges 18–75 - NCT07788196RecruitingPhase 2
Adding anti-HER2 therapy after surgery for early-stage gastric cancer
This trial tests whether adding a targeted therapy (anti-HER2) to standard chemotherapy after surgery can improve outcomes for people with early-stage gastric cancer that has high HER2 levels. It aims to see if the combination is more effective than chemotherapy alone.
Xi'an, ShaanxiAges 18 years+ - NCT06560528RecruitingPhase 2
Drug combo before & after surgery for HER2+ stomach cancer
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06572319RecruitingPhase 1/Phase 2
Combination drug trial for HER2-positive stomach cancer
This trial tests two drugs, disitamab vedotin and trastuzumab, for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or come back after at least one prior treatment. The goal is to see if this combination can help shrink tumors.
Hangzhou, ZhejiangAges 18–75 - NCT07689851RecruitingPhase 2
Chemoradiotherapy plus an immunotherapy for advanced gastric cancer
This trial studies a new immunotherapy drug (SHR-1701) combined with standard chemoradiotherapy for people with advanced stomach or esophagus cancer that cannot be surgically removed. The goal is to see if adding this immune treatment helps control the tumor better than standard treatments alone.
Shenzhen, GuangdongAges 18–75 - NCT07631000RecruitingPhase 2
Cadonilimab with chemotherapy for stomach cancer surgery
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy before surgery for stomach or gastroesophageal junction cancer. The goal is to shrink the tumor and improve outcomes for patients who are candidates for surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT05640830RecruitingPhase 1/Phase 2
Trastuzumab, bevacizumab, and paclitaxel for HER2-positive stomach cancer
This trial tests a combination of anti-cancer medicines for HER2-positive advanced stomach cancer that has already been treated once. It may help shrink tumors and slow the disease by targeting HER2 and blocking tumor blood supply.
SeoulAges Any age - NCT07552402Recruiting
Oral Paclitaxel Plus Fruquintinib for Advanced Stomach Cancer
This trial tests a combination of two oral drugs (paclitaxel and fruquintinib) for advanced stomach cancer that has already been treated with one round of chemotherapy. The goal is to see if this combination helps control the cancer better than other standard second-line treatments.
Shijiazhuang, HebeiAges 18–75 - NCT07533825Enrolling by invitation
Minimally Invasive Surgery Staging for Advanced Stomach Cancer
This trial tests whether a minimally invasive camera-guided surgical procedure (laparoscopy) can better detect hidden cancer spread in patients with advanced stomach cancer. The goal is to help doctors plan the best treatment and improve outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06767449Recruiting
Zolbetuximab for Claudin18.2 positive stomach cancer
This trial is for people with advanced stomach cancer that has a specific protein called Claudin18.2 and is HER2-negative. It tests whether continuing zolbetuximab—a drug that targets this protein—can help control the cancer.
SeoulAges 19 years+ - NCT07464470Recruiting
Comparing stomach cancer and brain metastasis genetics
This trial studies stomach and esophageal cancers that spread to the brain. It compares the genetic makeup of the original tumor to the brain metastasis, which may help find better treatments.
MoscowAges 18 years+ - NCT06791083RecruitingPhase 2
Envafolimab, Fruquintinib, and chemo before gastric cancer surgery
This trial tests a combination of two targeted drugs (Envafolimab and Fruquintinib) plus chemotherapy given before surgery for certain types of stomach cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Fuzhou, FujianAges 18–75 - NCT07432295RecruitingPhase 2
Givastomig plus nivolumab and chemo for advanced stomach cancer
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Goodyear, ArizonaAges 18 years+ - NCT07334431RecruitingPhase 1/Phase 2
A trial of fruquintinib, trastuzumab, and chemo for HER2-positive stomach cancer
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
Zhengzhou, HenanAges 18–75 - NCT07315854RecruitingPhase 2
Immunotherapy combo plus chemo for untreated stomach cancer
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
Beijing, Beijing MunicipalityAges 18–80 - NCT07320586RecruitingPhase 2
Carilizumab and chemo for advanced gastric cancer
This trial tests a combination of carilizumab (an immunotherapy) and albumin paclitaxel (a chemotherapy drug) for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first-line treatment. It aims to see if this second-line option can help control the cancer.
Jinan, ShandongAges 18–75 - NCT07194005RecruitingPhase 2
Combination therapy for HER2 1+/2+ advanced stomach cancer
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07198724RecruitingPhase 1/Phase 2
A study of elacestrant plus Enhertu for advanced breast cancer
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
Boston, MassachusettsAges 18 years+
Hear when a new HER2 + Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 + gastric cancer?
- Yes. Clin2 currently lists 145 recruiting her2 + gastric cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 + gastric cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 + gastric cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.